Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), 46, Avenue du Bugnon, 1011, Lausanne, Switzerland.
Nuclear Medicine and Molecular Imaging, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.
J Nephrol. 2023 May;36(4):1047-1058. doi: 10.1007/s40620-023-01569-0. Epub 2023 Feb 2.
Renal scintigraphy (RS) is occasionally performed to assess the risk of persistent renal failure (PRF) in patients with acute kidney disease (AKD). However, its diagnostic performance has never been assessed.
We identified all patients with AKD for whom RS was performed in our institution between 2010 and 2017. PRF was defined as persistently low (< 33% of baseline) estimated glomerular filtration rates (eGFR), 1 year after RS. Nuclear medicine specialists reviewed RS data and rated, for each patient, the likelihood of PRF ("PRF score"). We evaluated the performance to predict PRF (area under the ROC curve (AUC)) of RS-derived parameters such as renal accumulation index, accumulation slope, and new parameters derived from serial kidney activity counts. We tested the ability of those parameters to improve a clinical model including hypertension, diabetes, AKI severity and baseline eGFR. Finally, we conducted sensitivity analyses using alternate PRF definitions.
Among 97 patients included, 57 (59%) fulfilled the criteria for PRF. The PRF score was able to predict PRF with an AUC of 0.63. Similarly, the accumulation index and accumulation slope respective AUCs were 0.64 and 0.63. None of these parameters were able to improve the performance of the clinical model. Among new parameters, the 3rd/2nd minute activity ratio and 3rd/2nd minute activity slope had fair diagnostic performance (AUC 0.72 and 0.74, respectively) and improved the performance of the clinical model. Results were confirmed in sensitivity analyses.
Conventional renal scintigraphy can identify patients at high risk of PRF with a high specificity but a low sensitivity. New parameters, with comparable diagnostic abilities can be obtained within three minutes of injection.
肾闪烁显像术(RS)偶尔用于评估急性肾损伤(AKI)患者持续性肾功能衰竭(PRF)的风险。然而,其诊断性能从未得到评估。
我们确定了 2010 年至 2017 年期间在我院进行 RS 的所有 AKI 患者。PRF 定义为 RS 后 1 年持续(<33%的基线)估计肾小球滤过率(eGFR)。核医学专家回顾了 RS 数据,并对每位患者的 PRF 可能性(“PRF 评分”)进行了评分。我们评估了 RS 衍生参数(如肾摄取指数、摄取斜率和从连续肾脏活动计数中得出的新参数)预测 PRF 的性能(ROC 曲线下面积(AUC))。我们测试了这些参数改善包括高血压、糖尿病、AKI 严重程度和基线 eGFR 在内的临床模型的能力。最后,我们使用替代 PRF 定义进行了敏感性分析。
在 97 例患者中,57 例(59%)符合 PRF 标准。PRF 评分能够预测 PRF,AUC 为 0.63。类似地,摄取指数和摄取斜率的 AUC 分别为 0.64 和 0.63。这些参数均不能提高临床模型的性能。在新参数中,第 3/2 分钟活动比和第 3/2 分钟活动斜率具有较好的诊断性能(AUC 分别为 0.72 和 0.74),并提高了临床模型的性能。敏感性分析结果得到了证实。
传统的肾闪烁显像术可以识别高风险 PRF 患者,特异性高,但敏感性低。在注射后三分钟内即可获得具有相当诊断能力的新参数。